Piprozolin (CAS 17243-64-0) Global Market Research Report 2024

About the Market

Piprozolin is a gastrointestinal drug used to treat symptoms of irritable bowel syndrome (IBS). It is a prokinetic agent, meaning it helps to speed up the movement of food through the digestive tract. It works by increasing the amount of serotonin in the gut, which helps to reduce abdominal pain and discomfort. It is available in both oral and rectal forms. Common side effects include nausea, headache, and diarrhea. Piprozolin is a relatively new drug, having been approved by the FDA in 2018. It is currently available in the United States, Canada, and Europe. It is marketed as a prescription drug, and is typically prescribed by a doctor. The market for Piprozolin is growing, as more people are being diagnosed with IBS and other gastrointestinal disorders. It is becoming increasingly popular as a treatment option for those suffering from IBS, as it is relatively safe and effective. Companies in the Piprozolin market include Allergan, Merck, and Pfizer. Show Less Read more